articleThe LancetMar 1, 2008Closed access

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

SYShumpei YokotaTITomoyuki ImagawaMMMasaaki MoriTMTakako MiyamaeYAYukoh Aihara

Yokohama City University · Kagoshima University · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

793
total citations
FWCI
32.80
Percentile
100%
References
26
Citations per year

Authors

13

Topics & keywords

Topics
Keywords
  • Tocilizumab
  • Medicine
  • Placebo
  • Clinical endpoint
  • Internal medicine
  • Open label
  • Bristol-Myers
  • Rheumatology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding